Cargando…

The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study

BACKGROUND: Erectile dysfunction (ED) is common in older men with chronic kidney disease. Magnesium is essential for metabolism of nitric oxide which helps in penile erection. There is little information available about the influence of serum magnesium on ED. The aim of the study was to assess the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Toprak, Omer, Sarı, Yasin, Koç, Akif, Sarı, Erhan, Kırık, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340248/
https://www.ncbi.nlm.nih.gov/pubmed/28280316
http://dx.doi.org/10.2147/CIA.S129377
_version_ 1782512803242835968
author Toprak, Omer
Sarı, Yasin
Koç, Akif
Sarı, Erhan
Kırık, Ali
author_facet Toprak, Omer
Sarı, Yasin
Koç, Akif
Sarı, Erhan
Kırık, Ali
author_sort Toprak, Omer
collection PubMed
description BACKGROUND: Erectile dysfunction (ED) is common in older men with chronic kidney disease. Magnesium is essential for metabolism of nitric oxide which helps in penile erection. There is little information available about the influence of serum magnesium on ED. The aim of the study was to assess the influence of hypomagnesemia on ED in elderly chronic kidney disease patients. SUBJECTS AND METHODS: A total of 372 patients aged 65–85 years, with an estimated glomerular filtration rate of 60–15 mL/min/1.73 m(2), were divided into two groups according to serum magnesium levels: hypomagnesemia, n=180; and normomagnesemia, n=192. ED was assessed through the International Index of Erectile Function-5. Hypomagnesemia is defined as serum magnesium <1.8 mg/dL. RESULTS: The prevalence of ED was higher among hypomagnesemic subjects compared to that among normomagnesemics (93.3% vs 70.8%, P<0.001). Severe ED (62.8% vs 43.8%, P=0.037), mild-to-moderate ED (12.2% vs 5.2%, P=0.016), abdominal obesity (37.2% vs 22.9%, P=0.003), metabolic syndrome (38.4% vs 19.2%, P=0.026), proteinuria (0.83±0.68 vs 0.69±0.48 mg/dL, P=0.023), and C-reactive protein (6.1±4.9 vs 4.1±3.6 mg/L, P<0.001) were high; high-density lipoprotein cholesterol (48.8±14.0 vs 52.6±13.5 mg/dL, P=0.009), and albumin (4.02±0.53 vs 4.18±0.38 g/dL, P=0.001) were low in the hypomagnesemia group. Serum magnesium ≤1.85 mg/dL was the best cutoff point for prediction of ED. Hypomagnesemia (relative risk [RR] 2.27), age ≥70 (RR 1.74), proteinuria (RR 1.80), smoking (RR 21.12), C-reactive protein (RR 1.34), abdominal obesity (RR 3.92), and hypertension (RR 2.14) were predictors of ED. CONCLUSION: Our data support that ED is related to hypomagnesemia in elderly patients with moderately to severely reduced kidney function.
format Online
Article
Text
id pubmed-5340248
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53402482017-03-09 The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study Toprak, Omer Sarı, Yasin Koç, Akif Sarı, Erhan Kırık, Ali Clin Interv Aging Original Research BACKGROUND: Erectile dysfunction (ED) is common in older men with chronic kidney disease. Magnesium is essential for metabolism of nitric oxide which helps in penile erection. There is little information available about the influence of serum magnesium on ED. The aim of the study was to assess the influence of hypomagnesemia on ED in elderly chronic kidney disease patients. SUBJECTS AND METHODS: A total of 372 patients aged 65–85 years, with an estimated glomerular filtration rate of 60–15 mL/min/1.73 m(2), were divided into two groups according to serum magnesium levels: hypomagnesemia, n=180; and normomagnesemia, n=192. ED was assessed through the International Index of Erectile Function-5. Hypomagnesemia is defined as serum magnesium <1.8 mg/dL. RESULTS: The prevalence of ED was higher among hypomagnesemic subjects compared to that among normomagnesemics (93.3% vs 70.8%, P<0.001). Severe ED (62.8% vs 43.8%, P=0.037), mild-to-moderate ED (12.2% vs 5.2%, P=0.016), abdominal obesity (37.2% vs 22.9%, P=0.003), metabolic syndrome (38.4% vs 19.2%, P=0.026), proteinuria (0.83±0.68 vs 0.69±0.48 mg/dL, P=0.023), and C-reactive protein (6.1±4.9 vs 4.1±3.6 mg/L, P<0.001) were high; high-density lipoprotein cholesterol (48.8±14.0 vs 52.6±13.5 mg/dL, P=0.009), and albumin (4.02±0.53 vs 4.18±0.38 g/dL, P=0.001) were low in the hypomagnesemia group. Serum magnesium ≤1.85 mg/dL was the best cutoff point for prediction of ED. Hypomagnesemia (relative risk [RR] 2.27), age ≥70 (RR 1.74), proteinuria (RR 1.80), smoking (RR 21.12), C-reactive protein (RR 1.34), abdominal obesity (RR 3.92), and hypertension (RR 2.14) were predictors of ED. CONCLUSION: Our data support that ED is related to hypomagnesemia in elderly patients with moderately to severely reduced kidney function. Dove Medical Press 2017-02-24 /pmc/articles/PMC5340248/ /pubmed/28280316 http://dx.doi.org/10.2147/CIA.S129377 Text en © 2017 Toprak et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Toprak, Omer
Sarı, Yasin
Koç, Akif
Sarı, Erhan
Kırık, Ali
The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study
title The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study
title_full The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study
title_fullStr The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study
title_full_unstemmed The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study
title_short The impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study
title_sort impact of hypomagnesemia on erectile dysfunction in elderly, non-diabetic, stage 3 and 4 chronic kidney disease patients: a prospective cross-sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340248/
https://www.ncbi.nlm.nih.gov/pubmed/28280316
http://dx.doi.org/10.2147/CIA.S129377
work_keys_str_mv AT toprakomer theimpactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT sarıyasin theimpactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT kocakif theimpactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT sarıerhan theimpactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT kırıkali theimpactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT toprakomer impactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT sarıyasin impactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT kocakif impactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT sarıerhan impactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy
AT kırıkali impactofhypomagnesemiaonerectiledysfunctioninelderlynondiabeticstage3and4chronickidneydiseasepatientsaprospectivecrosssectionalstudy